



- (51) **International Patent Classification:**
C12N 15/113 (2010.01)
- (21) **International Application Number:**
PCT/US2022/082295
- (22) **International Filing Date:**
22 December 2022 (22.12.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/292,920 22 December 2021 (22.12.2021) US
63/308,373 09 February 2022 (09.02.2022) US
- (71) **Applicant:** **CAMP4 THERAPEUTICS CORPORATION** [US/US]; One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US).
- (72) **Inventors:** **SEHGAL, Alfica**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **MATTHEWS, Bryan J.**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **BUMCROT, David A.**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **CARAVELLA, Justin A.**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **GAMBOA, Mario Esteban Contreras**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Mass-

achusetts 02139 (US). **KELKAR, Rachana S.**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **JUNG, Yun Joon**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **LIU, Yuting**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **PAI, Rutuja Sudhakar**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **MOUKHEIBER, Henry Munir**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **ROY, Subhadeep**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US). **GUO, Yuchun**; c/o Camp4 Therapeutics Corporation, One Kendall Square, Building 1400 West, Suite 301, Cambridge, Massachusetts 02139 (US).

(74) **Agent:** **WIENS, Mayim E.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

(54) **Title:** MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS




FIG. 1

(57) **Abstract:** Described herein are methods of modulating gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for modulating the levels of gene products, for example, increasing expression of Carbamoyl-Phosphatase Synthetase 1 (CPS1), thereby treating diseases associated with aberrant gene expression.

[Continued on next page]

LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*